CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 9, 2021-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announced today that it intends to offer and sell 4,500,000 shares of its common stock in an underwritten public offering. In addition, KalVista intends to grant the underwriters a 30-day option to...

– Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) – – KVD900 Generally Safe and Well-Tolerated – – Conference Call to Discuss Trial Results Today at 8:30 a.m. ET – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb....